Danaher (DHR) Q3 2026 (Wed Oct 21 premarket) — revenue $6.6B (+8.5% Y/Y); GAAP diluted EPS <meta name="viewport" content="width=device-width, initial-scale=1.0" />.71 (+34.5% Y/Y), adj EPS $2.11 (+11.5% Y/Y); core revenue growth 3.0% / 5.5% ex-respiratory; Diagnostics total sales +17.0%; FY26 adj EPS guide RAISED to $8.57–$8.62 (from $8.45–$8.60); operating cash flow <meta name="viewport" content="width=device-width, initial-scale=1.0" />.9B; FCF <meta name="viewport" content="width=device-width, initial-scale=1.0" />.6B; DHR +~3.7% intraday to ~$232.50

.71 (+34.5% Y/Y), adj EPS $2.11 (+11.5% Y/Y); core revenue growth 3.0% / 5.5% ex-respiratory; Diagnostics total sales +17.0%; FY26 adj EPS guide RAISED to $8.57–$8.62 (from $8.45–$8.60); operating cash flow .9B; FCF .6B; DHR +~3.7% intraday to ~$232.50" /> .71 (+34.5% Y/Y), adj EPS $2.11 (+11.5% Y/Y); core revenue growth 3.0% / 5.5% ex-respiratory; Diagnostics total sales +17.0%; FY26 adj EPS guide RAISED to $8.57–$8.62 (from $8.45–$8.60); operating cash flow .9B; FCF .6B; DHR +~3.7% intraday to ~$232.50" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.